The ERCC1 C118T Polymorphism Predicts Clinical Outcomes of Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Meta-analysis Based on 22 Studies

Qian, Ying-Ying; Liu, Xin-You; Wu, Qian; Song, Xian; Chen, Xiao-Feng; Liu, Yi-Qian; Pei, Dong; Shen, Li-Zong; Shu, Yong-Qian

추천

검색

자료유형: 학술저널

저자정보: Qian, Ying-Ying (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Liu, Xin-You (Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University) Wu, Qian (Department of Neurology, The First Affiliated Hospital of Nanjing Medical University) Song, Xian (Department of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Pathogen Biology, Nanjing Medical University) Chen, Xiao-Feng (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Liu, Yi-Qian (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Pei, Dong (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Shen, Li-Zong (Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University) Shu, Yong-Qian (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제19호

발행연도: 2014.1

수록면: 8,383 - 8,390 (8page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Although the predictive value of the excision repair cross-complementing group 1 (ERCC1) C118T polymorphism in clinical outcomes of patients with colorectal cancer (CRC) receiving oxaliplatin-based chemotherapy has been evaluated in numerous published studies, the conclusions are conflicting. Therefore, we performed the present meta-analysis to determine the precise role of the ERCC1 C118T polymorphism in this clinical situation and help optimize individual chemotherapy. Materials and Methods: A multiple search strategy was used to identify eligible studies. Pooled odds ratios (ORs) and their 95% confidence intervals (CIs) were used to estimate objective response and oxaliplatin-induced toxicity, with hazard ratios (HRs) with 95%CIs for progression-free survival (PFS) and overall survival (OS). Results: A total of 22 studies including 2,846 CRC patients were eligible in the analysis. Overall, no significant correlation was found between the ERCC1 C118T polymorphism and objective response to oxaliplatin-based chemotherapy, in all patients or in the Asian and Caucasian subgroups. However, the pooled analysis showed that the PFS and OS were significantly shorter in patients who carried T/T or T/C genotypes of ERCC1 C118T as compared to the C/C genotype. On stratified analysis by ethnicity, the ERCC1 118T allele was associated with a favorable prognosis in Caucasians (PFS, HR=0.58, 95%CI: 0.24-1.44; OS, HR=0.38, 95%CI: 0.22-0.64) but an unfavorable prognosis in Asians (PFS, HR=2.49, 95%CI: 1.87-3.33; OS, HR=2.63, 95%CI: 1.87-3.69) based on a dominant model. In addition, we failed to find a statistically significant impact of ERCC1 C118T polymorphism on oxaliplatin-induced toxicity. Conclusions: The ERCC1 C118T polymorphism may have prognostic value in patients with CRC undergoing oxaliplatin-based chemotherapy.

#ERCC1 #oxaliplatin #prognosis #chemotherapy #meta-analysis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요